Skip to content
Nalbuphine
Nubain (nalbuphine) is a small molecule pharmaceutical. Nalbuphine was first approved as Nubain on 1982-01-01. It is used to treat postoperative pain in the USA. The pharmaceutical is active against kappa-type opioid receptor, mu-type opioid receptor, and delta-type opioid receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nalbuphine hydrochloride
Tradename
Company
Number
Date
Products
NALBUPHINE HYDROCHLORIDEAbbVieN-020200 DISCN1993-03-12
1 products
NUBAINPar PharmaceuticalN-018024 DISCN1982-01-01
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
nalbuphine hydrochlorideANDA2023-05-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
postoperative pain—D010149G89.18
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02A: Opioid analgesics
— N02AF: Morphinan derivatives, opiod analgesics
— N02AF02: Nalbuphine
HCPCS
Code
Description
J2300
Injection, nalbuphine hydrochloride, per 10 mg
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Tinea pedisD014008EFO_0007512B35.34—41—9
Tinea crurisD000084002B35.61—21—4
TineaD014005EFO_0007510B35.4———2—2
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Tinea capitisD014006B35.0—1———1
OnychomycosisD014009B35.1—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNALBUPHINE
INNnalbuphine
Description
Nalbuphine is an organic heteropentacyclic compound. It has a role as a mu-opioid receptor antagonist and an opioid analgesic. It derives from a hydride of a morphinan.
Classification
Small molecule
Drug classnarcotic agonists/antagonists (normorphine type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
Identifiers
PDB—
CAS-ID20594-83-6
RxCUI7238
ChEMBL IDCHEMBL895
ChEBI ID7454
PubChem CID5311304
DrugBankDB00844
UNII IDL2T84IQI2K (ChemIDplus, GSRS)
Target
Agency Approved
OPRK1
OPRK1
OPRM1
OPRM1
OPRD1
OPRD1
Organism
Homo sapiens
Gene name
OPRK1
Gene synonyms
OPRK
NCBI Gene ID
4986
Protein name
kappa-type opioid receptor
Protein synonyms
kappa opioid receptor, Opiate receptor, kappa-1
Uniprot ID
Q499G4
Mouse ortholog
Oprk1 (18387)
kappa-type opioid receptor (P33534)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,013 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nalbuphine hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
91 adverse events reported
View more details